- In early March 2026, Omada Health launched its GLP-1 Flex Care program for employer clients and reported fourth-quarter 2025 revenue of US$75.85 million with net income of US$5.16 million, alongside full-year 2025 revenue of US$260.21 million and reduced annual net loss of US$12.78 million.
- By combining a cash-pay GLP-1 access model that limits employers’ drug spend with improving profitability metrics, Omada is positioning its virtual care platform as both a cost-control and outcomes-focused partner for benefit sponsors.
- Next, we will examine how Omada’s GLP-1 Flex Care launch reshapes the company’s investment narrative and long-term virtual care positioning.
Invest in the nuclear renaissance through our list of 85 elite nuclear energy infrastructure plays powering the global AI revolution.
Omada Health Investment Narrative Recap
To own Omada Health, you need to believe that employers and health plans will keep turning to integrated virtual care platforms to manage obesity and cardiometabolic risk, and that Omada can translate that role into healthier margins over time. The GLP-1 Flex Care launch and stronger 2025 results reinforce Omada’s near term catalyst around GLP-1 coordination, while the main risk is that heavy 2026 investment in prescribing and AI tools could outpace revenue contribution and slow progress toward profitability.
Among the latest announcements, the 2026 revenue outlook of US$312 million to US$322 million is especially relevant. It sets a higher bar for Omada just as GLP-1 Flex Care expands its role in obesity care, tying the company’s execution on this program directly to whether it can meet guidance without stretching its cost base and stalling progress toward its long term margin ambitions.
Yet investors should also weigh how Omada’s large planned 2026 spend on GLP-1 and AI could expose them to...
Read the full narrative on Omada Health (it's free!)
Omada Health's narrative projects $434.1 million revenue and $23.7 million earnings by 2028. This requires 23.2% yearly revenue growth and a $49.9 million earnings increase from -$26.2 million today.
Uncover how Omada Health's forecasts yield a $28.90 fair value, a 106% upside to its current price.
Exploring Other Perspectives
The most optimistic analysts were already modeling about 26.6% annual revenue growth and future earnings of roughly US$25.7 million, which is far more upbeat than consensus and assumes Omada’s GLP-1 heavy strategy and AI investments translate cleanly into scale and profitability, even though the latest GLP-1 Flex Care launch could eventually either support or challenge those expectations in ways that different investors will view very differently.
Explore 3 other fair value estimates on Omada Health - why the stock might be worth just $20.19!
Form Your Own Verdict
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Omada Health research is our analysis highlighting 3 key rewards that could impact your investment decision.
- Our free Omada Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Omada Health's overall financial health at a glance.
Seeking Other Investments?
Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:
- Find 50 companies with promising cash flow potential yet trading below their fair value.
- Capitalize on the AI infrastructure supercycle with our selection of the 35 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
- Uncover the next big thing with 31 elite penny stocks that balance risk and reward.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com